Last reviewed · How we verify
RGI-7000
At a glance
| Generic name | RGI-7000 |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Rash
- Diarrhea
- Stomatitis
- Vomiting
- Decreased Appetite
- Abdominal Pain
- Fatigue
- Platelet Count Decreased
- Anaemia
- Muscosal Inflammation
- Alanine Aminotransferase increased
Key clinical trials
- RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2)
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RGI-7000 CI brief — competitive landscape report
- RGI-7000 updates RSS · CI watch RSS